Database→GH Fragment 176-191

Tier 4Fat LossMetabolicPREMIUM

GH Fragment 176-191

Human Growth Hormone Fragment 176-191 (hGH Frag 176-191; HGH Fragment 176-191)

Not FDA-approved for any indication. Not a licensed drug. Sold as research chemical only. Excluded from 503A compounding list consideration (FDA, December 2024 decision covers AOD-9604; same rationale applies). Prohibited under WADA S2 (Growth Hormone Fragments) since 2013, explicitly listed by name alongside AOD-9604. Both in-competition and out-of-competition prohibition apply.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

GH Fragment 176-191 is the unmodified 16-amino-acid C-terminal fragment of human growth hormone (residues 176-191), identified as responsible for growth hormone's lipolytic activity. It differs from AOD-9604 (profiled at order 33) by a single amino acid at the N-terminus: phenylalanine versus tyrosine. Critically, GH Fragment 176-191 has no published human clinical trial. Every human clinical finding in this peptide class belongs to AOD-9604 specifically. Animal evidence shows significant fat oxidation and weight loss in obese mice without GH receptor activation or IGF-1 elevation. WADA explicitly names both AOD-9604 and hGH 176-191 as prohibited growth hormone fragments under S2.

🔒

Full Profile: Premium Members Only

The complete GH Fragment 176-191 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use